Advice

following a full submission assessed under the end of life and ultra-orphan process:

nivolumab (Opdivo®) is accepted for use within NHS Scotland.

Indication under review: the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.

In an open-label, single-arm study, a clinically meaningful objective response rate was achieved in patients with relapsed or refractory cHL treated with nivolumab.
SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost effectiveness of nivolumab and is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

Download detailed advice349KB (PDF)

Download

Medicine details

Medicine name:
nivolumab (Opdivo)
SMC ID:
1240/17
Indication:
For the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.
Pharmaceutical company
Bristol-Myers Squibb Pharmaceuticals Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Accepted
Date advice published:
10 July 2017